Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022

July 15, 2022 11:47 UTC

EVANSTON, Ill.--(BUSINESS WIRE)--AptinyxInc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business highlights.

To access the live conference call, please dial (888) 660-6390 (domestic) or (929) 203-1902 (international) and refer to conference ID 4855909. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including fibromyalgia, cognitive impairment, and post-traumatic stress disorder. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.


Investor & Media Contact:
Patrick Flavin
Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com


Source: Aptinyx Inc.

Back to news